↓ Skip to main content

Dove Medical Press

Article Metrics

Mid-regional pro-adrenomedullin and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, March 2017
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
38 Mendeley
Title
Mid-regional pro-adrenomedullin and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study
Published in
International Journal of Chronic Obstructive Pulmonary Disease, March 2017
DOI 10.2147/copd.s126400
Pubmed ID
Authors

Martin Dres, Pierre Hausfater, Frantz Foissac, Maguy Bernard, Luc-Marie Joly, Mustapha Sebbane, Anne-Laure Philippon, Cédric Gil-Jardiné, Jeannot Schmidt, Maxime Maignan, Jean-Marc Treluyer, Nicolas Roche

Abstract

Exacerbations of COPD (ECOPD) are a frequent cause of emergency room (ER) visits. Predictors of early outcome could help clinicians in orientation decisions. In the current study, we investigated whether mid-regional pro-adrenomedullin (MR-proADM) and copeptin, in addition to clinical evaluation, could predict short-term outcomes. This prospective blinded observational study was conducted in 20 French centers. Patients admitted to the ER for an ECOPD were considered for inclusion. A clinical risk score was calculated, and MR-proADM and copeptin levels were determined from a venous blood sample. The composite primary end point comprised 30-day death or transfer to the intensive care unit or a new ER visit. A total of 379 patients were enrolled in the study, of whom 277 were eventually investigated for the primary end point that occurred in 66 (24%) patients. In those patients, the median (interquartile range [IQR]) MR-proADM level was 1.02 nmol/L (0.77-1.48) versus 0.83 nmol/L (0.63-1.07) in patients who did not meet the primary end point (P=0.0009). In contrast, copeptin levels were similar in patients who met or did not meet the primary end point (P=0.23). MR-proADM levels increased with increasing clinical risk score category: 0.74 nmol/L (0.57-0.89), 0.83 nmol/L (0.62-1.12) and 0.95 nmol/L (0.75-1.29) for the low-, intermediate- and high-risk categories, respectively (P<0.001). MR-proADM was independently associated with the primary end point (odds ratio, 1.65; 95% confidence interval [CI], 1.10-2.48; P=0.015). MR-proADM predicted the occurrence of primary end point with a sensitivity of 46% (95% CI, 33%-58%) and a specificity of 79% (95% CI, 74-84). MR-proADM but not copeptin was significantly associated with outcomes at 30 days, even after adjustment for clinical risk category. Overall, MR-proADM, alone or combined with the clinical risk score, was a moderate strong predictor of short-term outcomes.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 38 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 18%
Student > Bachelor 6 16%
Other 4 11%
Student > Ph. D. Student 4 11%
Researcher 2 5%
Other 4 11%
Unknown 11 29%
Readers by discipline Count As %
Medicine and Dentistry 12 32%
Nursing and Health Professions 5 13%
Unspecified 2 5%
Immunology and Microbiology 2 5%
Biochemistry, Genetics and Molecular Biology 1 3%
Other 5 13%
Unknown 11 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 October 2017.
All research outputs
#10,680,558
of 12,043,827 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#1,324
of 1,428 outputs
Outputs of similar age
#238,996
of 284,901 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#55
of 57 outputs
Altmetric has tracked 12,043,827 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,428 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 284,901 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 57 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.